University Hospital Zurich, Research and Education Office
https://www.usz.ch/forschung/Seiten/default.aspx
8091 Zürich, Rämistrasse 100
The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.
University Hospital Zurich, Research and Education Office
Rämistrasse 100
8091 Zürich
139 Ergebnisse für "therapeutics com com com" unter University Hospital Zurich, Research and Education Office
New Portfolio Start-Up: Stromal Therapeutics – USZ
... New Portfolio Start-Up: Stromal Therapeutics 25. May 2022 Let's welcome a new Start-Up to our ... portfolio: Stromal Therapeutics - Curing chronic inflammatory diseases through the manipulation of tissue ... New Portfolio Start-Up: Stromal Therapeutics – USZ ... https://www.usz.ch/en/new-portfolio-start-up-stromal- therapeutics/ ... New Portfolio Start-Up: Stromal Therapeutics – USZ ...
University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
887 Ergebnisse für "therapeutics com com com" unter University of Zurich
UZH - UFSP Dynamik Gesunden Alterns - Dipl. rer. com. Susanne Nieke
... Susanne Nieke, Dipl. rer. com. Wissenschaftliche Mitarbeiterin ... UZH - UFSP Dynamik Gesunden Alterns - Dipl. rer. com. Susanne Nieke ... UZH - UFSP Dynamik Gesunden Alterns - Dipl. rer. com. Susanne Nieke Home Hauptnavigation Suche ... UZH - UFSP Dynamik Gesunden Alterns - Dipl. rer. com. Susanne Nieke ...
UZH - URPP Dynamics of Healthy Aging - Dipl. rer. com. Susanne Nieke
... Susanne Nieke, Dipl. rer. com. Wissenschaftliche Mitarbeiterin ... UZH - URPP Dynamics of Healthy Aging - Dipl. rer. com. Susanne Nieke ... UZH - URPP Dynamics of Healthy Aging - Dipl. rer. com. Susanne Nieke Home Main navigation Search ... UZH - URPP Dynamics of Healthy Aging - Dipl. rer. com. Susanne Nieke ...
ETH Entrepreneurship
https://ethz.ch/en/industry/entrepreneurship.html
8952 Schlieren, Wagistrasse 18
Excellence in entrepreneurship at ETH Zurich is driven by world-class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions.
ETH Entrepreneurship
Wagistrasse 18
8952 Schlieren
1516 Ergebnisse für "therapeutics com com com" unter ETH Entrepreneurship
Consequences of pseudo-participatory approaches towards post-disast...
... com ... com ...
Consequences of pseudo-participatory approaches towards post-disast...
... com ... com ...
Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
992 Ergebnisse für "therapeutics com com com" unter Somagenetix
Entrevista com João Adolfo Hansen por Eduardo Jorge de Oliveira, Jú...
... Entrevista com João Adolfo Hansen por Eduardo Jorge de Oliveira, Júlia de Carvalho Hansen e Marcela ... professor que, através do turno da noite lidou com a realidade brasileira de textos, dentre outros, os de ... Entrevista com João Adolfo Hansen por Eduardo Jorge de Oliveira, Júlia de Carvalho Hansen e Marcela ... Entrevista com João Adolfo Hansen por Eduardo Jorge de Oliveira, Júlia de Carvalho Hansen e Marcela ... Entrevista com João Adolfo Hansen por Eduardo Jorge de Oliveira, Júlia de Carvalho Hansen e Marcela ...
Entrevista com Raúl Antelo por Eduardo Jorge de Oliveira, Eduardo S...
... de Oliveira, Eduardo Jorge ; Sterzi, Eduardo ; Stigger, Verônica (2020). Entrevista com Raúl Antelo ... seminário Museus e materialidades da literatura. Com trânsito livre entre Brasil e Argentina, ou melhor, com ... Entrevista com Raúl Antelo por Eduardo Jorge de Oliveira, Eduardo Sterzi e Verônica Stigger ... Entrevista com Raúl Antelo por Eduardo Jorge de Oliveira, Eduardo Sterzi e Verônica Stigger ... Entrevista com Raúl Antelo por Eduardo Jorge de Oliveira, Eduardo Sterzi e Verônica Stigger ...
CUTISS AG
8952 Schlieren, Grabenstrasse 11
+41 44 244 36 60
info@cutiss.swiss
After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.
CUTISS AG
Grabenstrasse 11
8952 Schlieren
34 Ergebnisse für "therapeutics com com com" unter CUTISS AG
Fallstudie: denovoSkin™ in der rekonstruktiven pädiatrischen Verbre...
... Com ... Com ...
NovaGo Therapeutics AG
http://www.novagotherapeutics.com
8952 Schlieren, Wagistrasse 27
NovaGo Therapeutics is a biotech start-up company dedicated to the development of human antibody therapeutics that promote nerve repair and regeneration in the treatment of cerebral stroke and spinal cord injury. NovaGo is developing human antibody therapeutics against Nogo-A. Nogo-A is the most potent inhibitor of nerve fiber regeneration. Anti-NogoA treatment promotes recovery of function in several animal models of stroke. Novago Therapeutics' anti-NogoA treatment represents a novel, regenerative approach for stroke. Recovery of function in stroke and other neurological disorders will be a clinical breakthrough and have a major economic impact on health care.
NovaGo Therapeutics AG
Wagistrasse 27
8952 Schlieren
11 Ergebnisse für "therapeutics com com com" unter NovaGo Therapeutics AG
novaGo Promobility therapeutics
... strong impact on patients‘ outcome. NovaGo Therapeutics is a biotech start-up company dedicated to the ... development of human antibody therapeutics targeting cerebral stroke and spinal cord injury to stimulate nerve ... novaGo Promobility therapeutics ... novaGo Promobility therapeutics Menu Company About NovaGo Management Board of Directors Science ... novaGo Promobility therapeutics ...
Memo Therapeutics AG
https://memo-therapeutics.com/
8952 Schlieren, Wagistrasse 27
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Exploiting the power of our microfluidic single-cell molecular cloning and screening technologies we engage in antibody discovery across species and indications for proprietary and partnered projects. Our current pipeline features programmes in infectious diseases and immuno-oncology. MemoMAB discovery uses robust, simple and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency and sensitivity. MemoMAB captures and preserves entire B cell repertoires from any donor species and any B cell type in recombinant form and displays them in mammalian cells, maintaining the cognate heavy and light chain pairing of the original B cells throughout the process.
Memo Therapeutics AG
Wagistrasse 27
8952 Schlieren
1 Ergebnisse für "therapeutics com com com" unter Memo Therapeutics AG
Dr. Grabulovski Dragan - Memo Therapeutics AG
... Dr. Grabulovski Dragan - Memo Therapeutics AG ... Dr. Grabulovski Dragan - Memo Therapeutics AG Skip navigation Home Technology Pipeline Skip ... Dr. Grabulovski Dragan - Memo Therapeutics AG ...
ImmunOs Therapeutics AG
http://immunostherapeutics.com/
8952 Schlieren, Wagistrasse 14
ImmunOs Therapeutics AG is a clinical-stage biotechnology company developing the next generation of novel immunotherapies that enhance the efficacy of market leading checkpoint inhibitors and costimulatory agonists for cancer therapy. The company is actively discussing and exploring new strategic collaborations with leading global pharmaceutical companies.
ImmunOs Therapeutics AG
Wagistrasse 14
8952 Schlieren
36 Ergebnisse für "therapeutics com com com" unter ImmunOs Therapeutics AG
Careers | Immunos Therapeutics
... A position at ImmunOs Therapeutics AG is an opportunity to join a group of entrepreneurial ... employees committed to developing innovative therapeutics that improve the lives of patients with serious ... Careers | Immunos Therapeutics ... Careers | Immunos Therapeutics Home Company Our Leadership Board of Directors Scientific Advisory ... Careers | Immunos Therapeutics ...
Neurimmune Therapeutics AG
8952 Schlieren, Wagistrasse 18
+41 44 755 46 46
info@neurimmune.com
Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases.
Neurimmune Therapeutics AG
Wagistrasse 18
8952 Schlieren
88 Ergebnisse für "therapeutics com com com" unter Neurimmune Therapeutics AG
Neurimmune Holding AG | Biogen Idec and Neurimmune Therapeutics ann...
... News and Press Releases Biogen Idec and Neurimmune Therapeutics announce alliance to develop ... (NASDAQ: BIIB) and Neurimmune Therapeutics AG today announced they have entered into an agreement for the ... Neurimmune Holding AG | Biogen Idec and Neurimmune Therapeutics announce alliance to develop ... Neurimmune Therapeutics announce alliance to develop treatments for Alzheimer’s disease Cambridge, MA, and ... Neurimmune Holding AG | Biogen Idec and Neurimmune Therapeutics announce alliance to develop ...
Molecular Partners AG
http://www.molecularpartners.com
8952 Schlieren, Wagistrasse 14
+41 44 755 77 00
Molecular Partners AG is a clinical-stage biopharmaceutical company, located in Schlieren, Switzerland, that is developing a new class of therapies known as DARPin® therapies.
Molecular Partners AG
Wagistrasse 14
8952 Schlieren
83 Ergebnisse für "therapeutics com com com" unter Molecular Partners AG
Actavis confirms timeline for the start of phase III development of...
... ophthalmology Molecular Partners has a strong focus on creating differentiated therapeutics for retinal diseases ... ™, a product that inhibits both VEGF and PDGF, through preclinical and clinical development to com ... ophthalmology Molecular Partners has a strong focus on creating differentiated therapeutics for retinal diseases ... ™, a product that inhibits both VEGF and PDGF, through preclinical and clinical development to com ...
Shareholders of Molecular Partners AG approved all Board proposals ...
... also re-elected. The shareholders of Molecular Partners AG also approved the proposed respective com ... therapeutics. The DARPin technology has the potential to enable a “multi-benefit” approach to treatment which ... Partners AG also approved the proposed respective com-pensation amounts for the Board of Directors and the ... conventional monoclonal antibodies or other current-ly available protein therapeutics. The DARPin technology ...